Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

著者: C. Jillian Tsai, Jonathan T. Yang, Narek Shaverdian, Juber Patel, Annemarie F. Shepherd, Juliana Eng, David Guttmann, Randy Yeh, Daphna Y. Gelblum, Azadeh Namakydoust, Isabel R. Preeshagul, Shanu Modi, Andrew D. Seidman, Tiffany A. Traina, Pamela Drullinsky, Jessica Flynn, Jessica Flynn, Zhigang Zhang, Erin F. Gillespie, Daniel R. Gomez, Nancy Y. Lee, Michael F. Berger, Mark E. Robson, Mark E Robson, Jorge S Reis-Filho, Charles M. Rudin, Simon N. Powell, Michael F. Berger, Jacqueline Bromberg, Linda Chen, Chau T. Dang, Jeeban P. Das, Pamela Drullinsky, Julianna Eng, Jessica Flynn, Daphna Y. Gelblum, Erin F. Gillespie, Jeffrey Girshman, Daniel R. Gomez, Ayca Gucalp, David Guttmann, Carla Hajj, Daniel S. Higginson, Afsheen N. Iqbal, Atif J. Khan, Quincey LaPlant, Nancy Y. Lee, J.M. Mann, Shanu Modi, Azadeh Namakydoust, Kenneth Ng, Juber Patel, Simon N. Powell, Isabel R. Preeshagul, Isabel Preeshagul, Marsha Reyngold, Marsha Reyngold, Nadeem Riaz, Mark E. Robson, Charles M. Rudin, Rachel Sanford, Andrew D. Seidman, Ronak Shah, Narek Shaverdian, Annemarie F. Shepherd, Jacob Y. Shin, Steven Sugarman, Tiffany A. Traina, C. Jillian Tsai, Abraham J. Wu, Amy Xu, Abraham J Wu, Randy Yeh, Jonathan T Yang, Wanqing Iris Zhi, Zhigang Zhang, Wanqing Iris Zhi - The Lancet 2023 被引用: 255